A small molecule called SK-129 stopped a neuronal protein from clumping together and spreading between brain cells in laboratory models of Parkinson's disease and related disorders, according to research published in Science Translational Medicine. The work comes from the Magzoub lab at NYU Abu Dhabi and the Kumar lab at the University of Denver, working with international collaborators.
The target matters because the same protein aggregation process drives a family of conditions that includes Parkinson's disease, Lewy body dementia and multiple system atrophy. As the protein misfolds, accumulates and passes from cell to cell, it damages neurons over time. No approved therapy currently interrupts that process; existing options address symptoms rather than the underlying disease mechanism.
SK-129 was designed specifically to interfere with that buildup, and the team put it through a broad set of tests: human cells, tissue derived from patients, and living organisms. Across all of those models, the molecule reduced the harmful effects associated with the disease - a consistency that strengthens the case for pursuing it further.
That said, this is preclinical work. Reducing protein aggregation in cells, patient-derived tissue and animal models is a necessary step, but it is a long way from showing that a compound slows disease in people. The finding's real value for now is as a proof of principle that the aggregation and spread of this protein can be blocked at all, which is the point at which a treatment for these conditions could shift from managing symptoms to altering their course.